Corbus Pharmaceuticals Announces Dosing of First Patient in Its First-In-Human Study of CRB-601 to Treat Patients With Advanced Solid Tumors
Corbus Pharmaceuticals Announces Dosing of First Patient in Its First-In-Human Study of CRB-601 to Treat Patients With Advanced Solid Tumors
CRB-601 is an anti-αvβ8 monoclonal antibody designed to block activation of latent TGFβ in the tumor micro-environment
CRb-601是一種抗αvβ8單克隆抗體，旨在阻止腫瘤微環境中潛在TGFβ的激活。
NORWOOD, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an oncology and obesity company with a diversified portfolio, today announced the dosing of the first patient in the Phase 1 portion of the clinical study of CRB-601 for the treatment of patients with advanced solid tumors (NCT06603844). CRB-601 is a monoclonal antibody targeting latent TGFβ activation-by blocking the integrin αVβ8. Pre-clinical data has demonstrated that CRB-601 overcomes tumor immune exclusion and enhances the activity of immune checkpoint inhibitors in vivo.
馬薩諸塞州諾伍德，2024年12月09日（環球新聞）-- Corbus Pharmaceuticals Holdings, Inc.（納斯達克：CRBP）（"Corbus"或"公司"），是一家擁有多元化投資組合的腫瘤學和肥胖症公司，今天宣佈在CRb-601治療晚期實質性腫瘤（NCT06603844)的臨床研究第1階段中爲首位患者進行給藥。CRb-601是一種單克隆抗體，通過阻斷整合素αVβ8來靶向潛在的TGFβ激活。前臨床數據已證明CRb-601克服了腫瘤免疫排斥，並增強了免疫檢查點抑制劑在體內的活性。
"CRB-601 offers an intriguing upstream approach to modulating TGFβ signaling and this dose escalation study could yield valuable insights along with the potential to see the immune system being mobilized and the prospect of tumors responding." said Dr. Dominic Smethurst, MA, MRCP, Chief Medical Officer of Corbus."
「CRb-601提供了一種引人注目的上游方法來調節TGFβ信號傳導，這項劑量遞增研究可能會帶來有價值的見解，並有可能看到免疫系統的動員和腫瘤反應的前景。」首席醫療官Dominic Smethurst博士說道。
"Dosing CRB-601 in a clinical trial marks an important milestone, bringing us closer to understanding its potential in the clinic and paving the way for advancements in an exciting corner of immunotherapy," said Dr. Jeffrey M. Clarke, MD., Associate Professor of Medicine, Associate Director of Thoracic Oncology Clinical Research Program, Duke Cancer Institute, Raleigh, NC. and a principal investigator in the CRB-601 study.
「在臨床試驗中給藥CRb-601標誌着一個重要的里程碑，使我們更接近了解其在臨床中的潛力，併爲免疫治療一個令人興奮的領域的進展鋪平道路，」杜克癌症研究所胸外科臨床研究項目副主任、醫學副教授Jeffrey m. Clarke博士說道，地點在北卡羅來納州羅利，同時也是CRb-601研究的主要研究者。
About Corbus
Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company with a diversified portfolio and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbus' pipeline includes CRB-701, a next generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody which blocks the activation of TGFβ expressed on cancer cells, and CRB-913, a highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on Facebook, LinkedIn and X.
關於Corbus
Corbus Pharmaceuticals Holdings, Inc.是一家腫瘤和肥胖症公司，擁有多元化的投資組合，致力於通過帶來創新的科學方法來幫助人們戰勝嚴重疾病，涉及廣爲人知的生物通路。Corbus的產品線包括CRb-701，這是一種針對癌細胞上Nectin-4表達的下一代抗體藥物結合物，以釋放細胞毒性載荷；CRb-601，一種抗整合素單克隆抗體，阻止癌細胞上TGFβ的激活；以及CRb-913，一種高度外周限制的CB1逆向激動劑，用於治療肥胖症。Corbus總部位於馬薩諸塞州諾伍德。如需獲取更多有關Corbus的信息，請訪問corbuspharma.com。請在Facebook、LinkedIn和X與我們聯繫。
Forward-Looking Statements
前瞻性聲明
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's restructuring, trial results, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.
本新聞稿包含根據《1933年證券法》第27A節和《1934年證券交易法》第21E節以及《私人證券訴訟改革法》的修正案定義的某些前瞻性陳述，包括與公司的重組、試驗結果、產品開發、臨床和監管時間表、市場機會、競爭地位、可能或假設的未來運營結果、業務策略、潛在增長機會以及其他具有預測性質的陳述相關的內容。這些前瞻性陳述基於我們經營的行業和市場的當前預期、估計、預測和項目，以及管理層當前的信念和假設。
These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
這些聲明可能通過使用前瞻性表達來識別，包括但不限於「期望」、「預期」、「打算」、「計劃」、「相信」、「估計」、「潛在」、「預測」、「項目」、「應該」、「會」等類似表達及其否定形式。這些聲明與未來事件或我們的財務表現有關，並涉及已知和未知的風險、不確定性以及其他因素，這些因素可能導致實際結果、表現或成就與任何未來結果、表現或成就在實質上存在重大差異，這些前瞻性聲明中所表達或暗示的。這些因素包括在公司提交給證券交易委員會的文件中列出的因素。潛在投資者被警告不要對這些前瞻性聲明過於依賴，這些聲明僅在本新聞稿發佈之日有效。公司沒有義務因新信息、未來事件或其他原因公開更新任何前瞻性聲明。
INVESTOR CONTACT:
投資者聯繫方式：
Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
smoran@corbuspharma.com
肖恩·莫蘭
首席財務官
Corbus製藥公司
smoran@corbuspharma.com
Bruce Mackle
Managing Director
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com
布魯斯·麥克爾
常務董事
生命科學顧問公司
bmackle@lifesciadvisors.com
Released December 9, 2024
發行於2024年12月9日
譯文內容由第三人軟體翻譯。